Eric M Dube reported a Travere Therapeutics share sale on Form 4

What did Eric M Dube report?

The SEC Form 4 reports an open-market sale of 128,065 shares of Travere Therapeutics (TVTX), at $52.97 each, for about $6.78M. The transaction date was Oct 15, 2026, and the form was filed on Oct 19, 2026, 4 days later.

The same person's filings also report an exercise or conversion of 44K TVTX derivative securities dated Oct 15, 2026. A footnote in the Form 4 mentions a planned or automatic transaction.

How does the sale fit the reported timing?

The sale took place 72 days after the company's results announcement of Aug 4, 2026, reported under 8-K Item 2.02. In the 455 days to Oct 19, 2026, OQRO holds 5 open-market sales by Travere Therapeutics insiders, counted once per person and day; 3 were made within 30 days after a results announcement.

As general background, many companies let insiders trade only in a window that opens after results. A sale can also follow an option exercise, a tax bill or a pre-arranged plan. A Form 4 does not say which of these applies here.

What other sales are in the comparison?

In the 365 days to Oct 19, 2026, OQRO holds 2 other open-market sales by this person, about $6.33M in total; 2 were at Travere Therapeutics. Across the company, 2 other open-market sales, about $6.33M by 1 insider, were filed in the 90 days to Oct 19, 2026.

In the 365 days before that 90-day period, 4 sales were filed, about $269K, an average of 1.0 per 90 days. These comparisons use only the filings OQRO holds.

What other public records were reported?

Fund 13F filings in the 90 days to Oct 19, 2026 show 3 new or larger positions and 1 smaller or closed position in Travere Therapeutics. For the quarter ended Jun 30, 2026, Stephens Investment Management Group LLC increased its position by 76,838 shares, and Driehaus Capital Management LLC increased its position by 156,616 shares. Farallon Capital Management, L.L.C. and Voloridge Investment Management, LLC sold out. A 13F is a quarter-end snapshot with no trade date.

ClinicalTrials.gov lists 2 company-sponsored studies updated in the period. The latest, Study NCT06247085, is a Phase 3 study with recruiting status and was updated on Oct 8, 2026; primary completion is listed for 2027-08. FINRA short interest for TVTX on the settlement date of Sep 30, 2026 was 12,655,839 shares, -2.32% on the previous report, or about 7.23 days of average volume.

What was on record around the trade date?

On Sep 21, 2026, 24 days before the sale, Travere Therapeutics filed a Form 8-K that OQRO classifies as a change involving a top executive or board member. The company's opening sentence says Travere Therapeutics, Inc. and Eric Dube, Ph.D., “mutually agreed to the timeline and terms surrounding the planned transition of Dr. Dube, who will step down from his position as the Company...” The Form 8-K of Sep 21, 2026 is on record.

TVTX closed at $52.79 on Oct 15, 2026, the last session on or before the trade date. From Sep 15, 2026 to Oct 15, 2026, the close moved from $62.51 to $52.79, a change of −15.5%. From Oct 15, 2026 to Oct 19, 2026, it moved from $52.79 to $50.49, a change of −4.4%. The filing does not explain these price moves; other news can move a price.

What this does not tell you?

A Form 4 reports a transaction; it does not say why it was made. Some purchases and sales follow trading windows or pre-arranged plans, and OQRO notes a plan only when a filing footnote says so. The footnote here mentions a planned or automatic transaction.

An 8-K item says what the company reported, not what it means for the share price. The price changes are listed as context only. This describes public filings and is not investment advice. For more filing context, see Travere Therapeutics on OQRO.